BR0213434A - Método para evitar demência em um paciente, e, uso de rosuvastatina ou seu sal farmaceuticamente aceitável - Google Patents
Método para evitar demência em um paciente, e, uso de rosuvastatina ou seu sal farmaceuticamente aceitávelInfo
- Publication number
- BR0213434A BR0213434A BR0213434-9A BR0213434A BR0213434A BR 0213434 A BR0213434 A BR 0213434A BR 0213434 A BR0213434 A BR 0213434A BR 0213434 A BR0213434 A BR 0213434A
- Authority
- BR
- Brazil
- Prior art keywords
- patient
- rosuvastatin
- pharmaceutically acceptable
- acceptable salt
- dementia
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title abstract 4
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title abstract 3
- 229960000672 rosuvastatin Drugs 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0103509A SE0103509D0 (sv) | 2001-10-19 | 2001-10-19 | Rosuvastatin in pre demented states |
| PCT/SE2002/001911 WO2003032995A1 (en) | 2001-10-19 | 2002-10-18 | Rosuvastatin in pre demented states |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0213434A true BR0213434A (pt) | 2004-11-09 |
Family
ID=20285721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0213434-9A BR0213434A (pt) | 2001-10-19 | 2002-10-18 | Método para evitar demência em um paciente, e, uso de rosuvastatina ou seu sal farmaceuticamente aceitável |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20060229321A1 (enExample) |
| EP (1) | EP1446123A1 (enExample) |
| JP (1) | JP2005505605A (enExample) |
| KR (1) | KR20040058201A (enExample) |
| CN (1) | CN1604780A (enExample) |
| AR (1) | AR036891A1 (enExample) |
| BR (1) | BR0213434A (enExample) |
| CA (1) | CA2463597A1 (enExample) |
| CO (1) | CO5580773A2 (enExample) |
| HU (1) | HUP0401798A3 (enExample) |
| IL (1) | IL161380A0 (enExample) |
| IS (1) | IS7218A (enExample) |
| MX (1) | MXPA04003631A (enExample) |
| NO (1) | NO20041840L (enExample) |
| PL (1) | PL369573A1 (enExample) |
| RU (1) | RU2004112422A (enExample) |
| SE (1) | SE0103509D0 (enExample) |
| WO (1) | WO2003032995A1 (enExample) |
| ZA (1) | ZA200402844B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7396927B2 (en) | 2003-08-28 | 2008-07-08 | Teva Pharmaceutical Industries Ltd. | Process for preparation of rosuvastatin calcium |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| WO2005051921A1 (en) | 2003-11-24 | 2005-06-09 | Teva Pharmaceutical Industries Ltd. | Crystalline ammonium salts of rosuvastatin |
| US7244844B2 (en) | 2003-12-02 | 2007-07-17 | Teva Pharmaceutical Industries Ltd. | Reference standard for characterization of rosuvastatin |
| JP2007508379A (ja) | 2004-07-13 | 2007-04-05 | テバ ファーマシューティカル インダストリーズ リミティド | Ｔｅｍｐｏ媒介型酸化段階を包含するロスバスタチンの調製方法 |
| CA2680693A1 (en) | 2005-02-22 | 2006-08-31 | Teva Pharmaceutical Industries Ltd. | Preparation of rosuvastatin |
| MX2007004427A (es) | 2005-08-16 | 2007-06-14 | Teva Pharma | Intermedio de rosuvastatina cristalina. |
| WO2012073256A1 (en) | 2010-11-29 | 2012-06-07 | Cadila Healthcare Limited | Salts of rosuvastatin |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| US7189703B2 (en) * | 1998-01-09 | 2007-03-13 | Intracell, Llc | Treatment and diagnosis of alzheimer's disease |
| AR022462A1 (es) * | 1999-02-06 | 2002-09-04 | Astrazeneca Uk Ltd | Uso de un agente que disminuye el colesterol |
| US20030100493A1 (en) * | 2001-07-19 | 2003-05-29 | Sol Weiss | Sublingual use of inhibitors in the biosynthesis of cholesterol |
-
2001
- 2001-10-19 SE SE0103509A patent/SE0103509D0/xx unknown
-
2002
- 2002-10-17 AR ARP020103895A patent/AR036891A1/es not_active Application Discontinuation
- 2002-10-18 JP JP2003535798A patent/JP2005505605A/ja active Pending
- 2002-10-18 RU RU2004112422/14A patent/RU2004112422A/ru not_active Application Discontinuation
- 2002-10-18 CA CA002463597A patent/CA2463597A1/en not_active Abandoned
- 2002-10-18 MX MXPA04003631A patent/MXPA04003631A/es not_active Application Discontinuation
- 2002-10-18 KR KR10-2004-7005585A patent/KR20040058201A/ko not_active Withdrawn
- 2002-10-18 HU HU0401798A patent/HUP0401798A3/hu unknown
- 2002-10-18 IL IL16138002A patent/IL161380A0/xx unknown
- 2002-10-18 WO PCT/SE2002/001911 patent/WO2003032995A1/en not_active Ceased
- 2002-10-18 CN CNA028253477A patent/CN1604780A/zh active Pending
- 2002-10-18 PL PL02369573A patent/PL369573A1/xx not_active Application Discontinuation
- 2002-10-18 BR BR0213434-9A patent/BR0213434A/pt not_active Application Discontinuation
- 2002-10-18 US US10/492,971 patent/US20060229321A1/en not_active Abandoned
- 2002-10-18 EP EP02783893A patent/EP1446123A1/en not_active Withdrawn
-
2004
- 2004-04-13 IS IS7218A patent/IS7218A/is unknown
- 2004-04-15 ZA ZA200402844A patent/ZA200402844B/en unknown
- 2004-04-19 CO CO04035705A patent/CO5580773A2/es not_active Application Discontinuation
- 2004-05-05 NO NO20041840A patent/NO20041840L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003032995A8 (en) | 2004-06-03 |
| JP2005505605A (ja) | 2005-02-24 |
| ZA200402844B (en) | 2005-01-24 |
| EP1446123A1 (en) | 2004-08-18 |
| NO20041840L (no) | 2004-05-05 |
| PL369573A1 (en) | 2005-05-02 |
| CN1604780A (zh) | 2005-04-06 |
| MXPA04003631A (es) | 2004-07-30 |
| CO5580773A2 (es) | 2005-11-30 |
| RU2004112422A (ru) | 2005-04-10 |
| AR036891A1 (es) | 2004-10-13 |
| HUP0401798A3 (en) | 2005-06-28 |
| IS7218A (is) | 2004-04-13 |
| WO2003032995A1 (en) | 2003-04-24 |
| HUP0401798A2 (hu) | 2005-01-28 |
| IL161380A0 (en) | 2004-09-27 |
| KR20040058201A (ko) | 2004-07-03 |
| CA2463597A1 (en) | 2003-04-24 |
| US20060229321A1 (en) | 2006-10-12 |
| SE0103509D0 (sv) | 2001-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0312947A (pt) | terapias para insuficiência renal empregando-se interferon-beta | |
| BRPI0108977B8 (pt) | compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo | |
| BR0111913A (pt) | Análogos de gabapentina para distúrbios do sono | |
| BR0111196A (pt) | Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus | |
| ZA9426B (en) | Use of riluzole for the treatment of Parkinson's Disease and Parkinsonian Syndromes | |
| BRPI0413974A (pt) | combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação | |
| NO922380D0 (no) | Substituerte 4-fenyl-4-piperidinkarboksamider med baade lokal anestetisk og analgetisk effekt samt fremgangsmaater for deres fremstilling | |
| BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
| BR9916860A (pt) | Método de reduzir colesterol do sangue e/outriglicerìdios do sangue em um indivìduo mamìfero,preparação em forma de unidade de dosagem, e,conjunto para administrar oralmente a mesma | |
| BR0314844A (pt) | Novo composto | |
| BR0314843A (pt) | Novo composto | |
| DK1001792T3 (da) | Anvendelse af fysiologisk acceptable vanadiumforbindelser, -salte og -komplekser | |
| BR0213434A (pt) | Método para evitar demência em um paciente, e, uso de rosuvastatina ou seu sal farmaceuticamente aceitável | |
| BR0211970A (pt) | Uso de bibn4096 em combinação com outras drogas antienxaqueca para o tratamento de enxaqueca | |
| BR9815098A (pt) | Uso de mirtazapina ou de um seu sal farmaceuticamente aceitável, e, processo para o tratamento de apnéias do sono em um aninal. | |
| EP1266663A4 (en) | INDUCER OF EOSINOPHILIC SPECIFIC APOPTOSIS | |
| BR0010084A (pt) | Composição farmacêutica, processos para prevenir, tratar ou inibir o desenvolvimento de retinopatia simples ou retinopatia proliferativa, e para aumentar potencial retiniano ou edema retiniano de mamìfero, e, uso de um composto | |
| BR0313655A (pt) | Uso de n-(3-metóxi-5-metilpirazin-2-il)-2-(4-[1, 3, 4-oxadiazol-2-il]fenil) piridina-3-sulfonamida, ou um sal do mesmo farmaceuticamente aceitável | |
| PT986393E (pt) | Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro | |
| DK0866711T3 (da) | Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö | |
| BR9910185A (pt) | Uso de um composto, e, processo para o tratamento de um paciente que sofre de, ou em risco de, uma doença micobacteriana | |
| KR910015300A (ko) | 부스피론 : 수면 무호흡증의 치료용도 | |
| BR0109119A (pt) | Uso de (r)-(-)-2-[5-(4-fluorofenil)-3-piridilmetil-aminometil]-cr omano e seus sais fisiologicamente aceitáveis | |
| BR0211358A (pt) | Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis | |
| BR0213410A (pt) | Usos farmacêuticos de bisfosfonatos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |